Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR) in combination with platinum-based chemotherapy has been for the decade standard of care for the treatment of head and neck squamous cell carcinomas (HNSCC) patients in the first-line recurrent and/or metastatic s...

Full description

Bibliographic Details
Main Authors: Edith Borcoman, Gregoire Marret, Christophe Le Tourneau
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cancers
Subjects:
head and neck squamous cell carcinoma
first-line treatment
immunotherapy
PD-L1
Online Access:https://www.mdpi.com/2072-6694/13/11/2573

Internet

https://www.mdpi.com/2072-6694/13/11/2573

Similar Items